GlassScriptPhysician profile
Samuel H Watson
NPI 1588090583
$5,426.65
in general payments reported to CMS, 2019-2025
33 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $1,000 · 2023: $627 · 2024: $1,428 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,957 · Consulting Fee: $175 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.91 |
| Consulting Fee | $175.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $864.45 | 2022-2024 | Axonics, Bulkamid |
| Antares Pharma, INC. | $447.49 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $445.38 | 2022-2025 | |
| Janssen Biotech, INC. | $420.86 | 2023-2025 | Erleada, Akeega |
| Endo USA, INC. | $396.03 | 2024-2025 | Xiaflex, Aveed, Edex |
| Sumitomo Pharma America, INC. | $381.37 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $297.32 | 2024-2025 | Barrigel, Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $241.35 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $223.21 | 2022-2024 | Xiaflex, Aveed, Edex |
| Amgen INC. | $175.00 | 2025 | Prolia |
| Penumbra, INC. | $149.97 | 2024 | Ruby Coil |
| Pfizer INC. | $136.88 | 2022-2024 | |
| Coloplast Corp | $131.04 | 2023-2024 | Speedicath |
| Tolmar, INC. | $117.29 | 2024-2025 | Eligard |
| Merck Sharp & Dohme LLC | $113.84 | 2022-2025 | Keytruda, Lynparza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $110.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $108.09 | 2025 | |
| Accord Healthcare, INC. | $102.15 | 2023-2025 | |
| Tolmar Pharmaceuticals, INC. | $60.66 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $55.37 | 2023-2025 | Trelstar, Tlando |
| Procept Biorobotics Corporation | $52.66 | 2024 | Aquabeam System |
| Telix Pharmaceuticals | $49.28 | 2023-2025 | Illuccix |
| Bioprotect Medical, INC. | $42.32 | 2025 | Bioprotect Balloon Implant System |
| Boston Scientific Corporation | $41.42 | 2023-2025 | Spaceoar Vue System - 10ml, Axonics |
| Azurity Pharmaceuticals, INC. | $41.14 | 2025 | Azmiro |
| Allergan, INC. | $38.93 | 2021-2022 | |
| Myovant Sciences INC. | $37.41 | 2022 | |
| Sun Pharmaceutical Industries INC. | $33.31 | 2024 | |
| Dendreon Pharmaceuticals LLC | $32.73 | 2024 | Provenge |
| Foundation Medicine, INC. | $22.79 | 2023 | |
| Acerus Pharmaceuticals Corporation | $20.14 | 2021 | |
| Urovant Sciences INC | $19.90 | 2022 | |
| Tempus Ai, INC | $16.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.